Temozolomide is a second-generation alkylating agent. It is an oral chemotherapeutic drug used to treat brain cancers such as adult malignant glioma and malignant melanoma. It was developed by Merck & Co., Inc. The drug was approved to enter the Chinese market under the trade name TEMODAL in 2007. By 2020, Temozolomide has been included in China’s Class B medical insurance. There are many manufacturers in the Chinese market in 2020, among which Merck Sharp & Dohme Ltd is the main manufacturer.
According to CRI’s market research, the sales value of Temozolomide in the Chinese market increased year by year from 2016 to 2019. Due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the sales value of Temozolomide in the Chinese market decreased to CNY793 million in 2020 and the CAGR of Temozolomide in sales value from 2016 to 2020 is 9.04%.
CRI expects that with the relief of COVID-19, the sales value of Temozolomide in the Chinese market will have a restorative growth from 2021 to 2025. In addition, as the incidence of primary brain cancer increases, other cancers can cause secondary brain cancer. Therefore, with the widespread use of digital electronic products and the increase in the incidence of other cancers, the incidence of brain cancer is also increasing year by year, the sales value and sales volume of Temozolomide for the treatment of brain cancer will continue to increase. At the same time, Temozolomide has the characteristics of easily penetrating the blood-cerebrospinal fluid barrier and mild adverse reactions. CRI predicts that the sales value and sales volume of Temozolomide in the Chinese market will have room for increase from 2021 to 2025.
- -The impact of COVID-19 on China’s Temozolomide market
- – Sales value of China’s Temozolomide 2016-2020
- – Competitive landscape of China’s Temozolomide market
- – Prices of Temozolomide in China
- – Prices of Temozolomide in China by regions and manufacturers
- – Analysis on factors affecting the development of China’s Temozolomide market
- – Prospect of China’s Temozolomide market from 2021 to 2025